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SS27.
Transaxillary First Rib Resection for Neurogenic Tho-
racic Outlet Syndrome (NTOS) Has Better Outcomes
in Younger Patients
Julie Freischlag, Kendall C. Likes, Ying Wei Lum, Benja-
min S. Brooke, Holly Grunebach. Johns Hopkins Medical
Institution, Baltimore, MD
Objectives: Surgical management of neurogenic tho-
racic outlet syndrome (NTOS) remains suspect due to the lack
of predictors of success. We sought to examine the effects of
patient demographics, etiology, duration of symptoms and
the selective use of lidocaine and botulinum toxin anterior
scalene blocks on outcomes of patients undergoing transax-
illary first rib resection and scalenectomy (FRRS) for
NTOS.
Methods: Between 2003-9, patients with NTOS who
had failed physical therapy and had FRRS were retrospec-
tively reviewed from a prospectively maintained database.
Patients were stratified to age groups 40 and 40 years.
Bivariate and multivariate statistical models of analysis were
used.
Results: 159 FRRSs (16 patients bilateral, 3 patients
with cervical ribs, 84.3% female, median age 37 years;
range 21-64) were identified. 96 were 40 and 63 40
years. After a median follow-up of 12 months, FRRS was
more likely to relieve symptoms in patients 40 versus
40 years (90% vs 77.8%; p0.05). Etiology was similar
in both groups: trauma 43% vs 46% and chronic repeti-
tive motion 57% vs 54%. Duration of symptoms was less
in the 40 group (38.4 vs 66 months; p0.05). More
patients in the 40 group had other spine, shoulder or
arm operations (38% vs 18%; p0.05). Lidocaine blocks
were positive in 89% (50/56) in the 40 group and 93%
(40/43) in the 40 group. After adjusting for patient
presenting factors in multivariate analysis, patients 40
years were more likely to have a successful outcome if
they had a successful lidocaine nerve block prior to FRRS
(p0.05). Botulinum toxin blocks were successful in less
patients, 40% (8/20) in the 40 group and 52.4%
(11/21) in the 40 group, but were not predictive of
symptom relief following FRRS.
Conclusions: NTOS patients 40 years achieve
more symptom relief following FRRS as compared to
patients 40 years. Patients and surgeons should be
aware of less success with age when undergoing FRRS.
In patients 40 years, the selective use of lidocaine
blocks is most beneficial.
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Prevalence of Malignancies Post-AAA Repair: An Eight
Years Comparable Longitudinal Study of EVAR vs
Open Repair(OR) in a Tertiary Referral University
Vascular Centre
Sherif Sultan2, Wael Tawfick1. 1Vascular & Endovascular
Surgery, Western Vascular Institute, Galway, Ireland; 2Gal-
way Clinic, Galway, Ireland
Objectives: We aim to quantify metachronous malig-
nancy following EVAR or OR. Primary endpoint is
development of malignancy following AAA-repair, and
malignancy/cardiovascular related mortality. Secondary
endpoints are prevalence of previous, or synchronous
malignancy, irradiation exposure and all cause survival.
Methods: From 2002-2010, of 2973 patients with
AAA, 409 underwent repair (267:EVAR, 142:OR). All
CTA, X-Ray and intra-operative radiation exposure were
analyzed.
Results: Mean radiation exposure during EVAR was
11.4 minutes vs. 4.8 minutes in OR patients who required
some form of endovascular re-intervention (P0.021).
Mean intra-operative radiation dosage was 19236.28 m Gy
cm2, in contrast to 7125.13 m Gy cm2 in OR patients
(P0.006). Total radiation dosage including CTA and
X-Ray was 81.37msv in EVAR and 36.71 msv in OR
(P0.001). Forty-three EVAR patients had malignancy VS
25 OR patients. Metachronous malignancy transpired in
3% of EVAR and 5.6% of OR(P0.027). No metachro-
nous malignancies occurred in patients requiring endovas-
cular re-intervention. Eight-year all cause survival was 62%.
60% in patients with malignancies and 69% in non-malig-
nant (P0.276). In malignant-EVARs, mortalities were
56% cardiovascular related, 33% malignancy related. In
non-malignant-EVARs, mortalities were 62% cardiovascu-
lar related and 38% other causes. In OR, all cause survival
was 61%. 64%in malignant-OR and 60% in non-malignant
(P0.107). In malignant-OR, mortalities were 56% car-
diovascular related 22% malignancy related. In non-malig-
nant OR, 72% were cardiovascular related. Median survival
post-EVAR was 37months with malignancy and 46months
without (P0.162, HR1.639, 95%CI0.652 to 7.331).
Post-OR, median survival was 35months with malignancy
and 43months without (P0.179, HR1.957, 95%CI
0.704 to 14.139).
Conclusions: EVAR is not an independent risk factor
for post-operative malignancies. EVAR and OR had iden-
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